Navigation Links
Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
Date:5/30/2012

SAN FRANCISCO, May 30, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the Jefferies 2012 Global Healthcare Conference at The Grand Hyatt New York on Tuesday, June 5, 2012 at 11:30 a.m. Eastern Time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until July 5, 2012.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic in development to treat chronic pain, has completed Phase 1 development and is being prepared for a Phase 2 study.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study for the treatment of metastatic breast cancer and in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 1 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics

(415) 482-5585Susan Noonan/SA Noonan Communications, LLC

(212) 966-3650Nektar Media Inquiries: Karen Bergman/BCC Partners

(650) 575-1509


'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/7/2020)... ... 2020 , ... Today RED Company founder and President, Carmela ... quickly source healthcare supplies . Due to her long-standing relationships within the ... making them available to U.S. businesses in a seamless manner for years through ...
(Date:4/5/2020)... , ... April 04, 2020 , ... ... from cancer patients now undergoing treatment. The company notes that new patient inquiries ... Coronavirus COVID-19 outbreak rose. , "Cancer patients feel safer with our telemedicine delivery," ...
(Date:4/2/2020)... (PRWEB) , ... April 02, 2020 , ... NCPDP has ... at the Meeting of the NCPDP Board of Trustees on Wednesday, May 6, 2020. ... Pooja Babbrah, M.B.A., PBM Practice Lead, Point-of-Care Partners, newly elected to the Board of ...
Breaking Medicine Technology:
(Date:4/2/2020)... ... April 02, 2020 , ... ... FDAnews Webinar, Tuesday April 7, 2020, 1:30-3:00 p.m. EDT, https://www.fdanews.com/cdssoftwareregulation ... of AI used to guide clinical management of the Coronavirus.* , Is one’s ...
(Date:4/2/2020)... ... April 02, 2020 , ... The Northern Virginia Community College Educational Foundation ... Debra Coffman Howe of Palm Beach, Florida. Ms. Howe is adding to her ... NOVA nursing is more important than ever given the current pandemic. Ms. Howe has ...
(Date:4/2/2020)... ORLEANS (PRWEB) , ... April 02, 2020 , ... ... while fetuses in their mother’s womb are encouraging their parents, grandparents, and guardians, ... from Purdue—reportedly up to $6 billion in funds will be made available by ...
(Date:4/1/2020)... ... April 02, 2020 , ... Medical Device Change Management, ... https://www.fdanews.com/mdchangemanagement , What change management method should one be using for ... often dependent on the type of change. Is it due to post-market design change, ...
(Date:4/1/2020)... ... 01, 2020 , ... American hospital workers are in desperate ... , Staffers are in particular need of face shields, which protect them from ... Street Journal reported that New York City mayor Bill de Blasio's office was ...
Breaking Medicine News(10 mins):